VANCOUVER, Oct. 11 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX)
announced today that it has received approval of their Clinical Trial
Application (CTA) from Health Canada to initiate a Phase I human clinical
trial of PRX302 to treat adult men with benign prostatic hyperplasia (BPH), or
enlarged prostates.
